Log in to your Inderes Free account to see all free content on this page.
Gubra
489 DKK +6.3%HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. See disclaimer.
13 investors are following this company
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.
Revenue
205.01M
EBIT %
-23.25 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
GUBRA
Daily low / high price
464 / 498
DKK
Market cap
8B DKK
Turnover
35.55M DKK
Volume
74K
Latest research
Latest videos
Financial calendar
Interim report
23.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Niels Vrang | 30.6 % | 30.6 % |
Jacob Jelsing | 27.5 % | 27.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Gubra (One-pager): Very high investor confidence in Gubra’s ability to bring obesity products to the market
Gubra - Presentation of Q2 report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio